(Q37913983)

25 August 2017

1 reference

title

The changing therapeutic landscape of castration-resistant prostate cancer (English)

1 reference

25 August 2017

1 reference

Timothy A Yap

1

1 reference

25 August 2017

Andrea Zivi

series ordinal

2

1 reference

25 August 2017

Aurelius Omlin

series ordinal

3

1 reference

25 August 2017

Johann S de Bono

series ordinal

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

9 August 2011

1 reference

Nature Reviews Clinical Oncology

25 August 2017

1 reference

25 August 2017

8

1 reference

25 August 2017

597-610

1 reference

25 August 2017

10

1 reference

25 August 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Estimates of cancer incidence and mortality in Europe in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Mechanisms underlying the development of androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Targeting CYP17: established and novel approaches in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Horizon scanning for novel therapeutics for the treatment of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Update on tubulin-binding agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

BRAF targeted therapy changes the treatment paradigm in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Autoantibody signatures in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Prostate cancer as a model for tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Drug development in oncology: classical cytotoxics and molecularly targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Envisioning the future of early anticancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Fusion in the ETS gene family and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Utilizing circulating tumor cells: challenges and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A decade in prostate cancer: from NMR to metabolomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Ligand-independent activation of the androgen receptor by insulin-like growth factor-I and the role of the MAPK pathway in skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Molecular pathways in the progression of hormone-independent and metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

RAS pathways in prostate cancer - mediators of hormone resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Interaction of IGF signaling and the androgen receptor in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

PSA as an intermediate end point in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Current and emerging treatment modalities for metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Demonstration of a rational strategy for human prostate cancer gene therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Immunotherapy for the treatment of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

The association between measures of progression and survival in castrate-metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Predictors of mortality after prostate-specific antigen failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.117

Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer.

31 March 2020

1 reference

12 December 2020

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug

1 reference

12 December 2020

Efficacy of low-dose dexamethasone in castration-refractory prostate cancer

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

1 reference

12 December 2020

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

1 reference

12 December 2020

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

1 reference

12 December 2020

Androgen receptor mutations in prostate cancer.

1 reference

12 December 2020

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

1 reference

12 December 2020

Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer

1 reference

12 December 2020

Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

1 reference

12 December 2020

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2006.24.18_SUPPL.4609

Identifiers

DOI

10.1038/NRCLINONC.2011.117

1 reference

25 August 2017

1 reference